Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,082 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Completed Phase 1Phase 2 Interventional Results available

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

NCT01084655
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700, Docetaxel, Prednisone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT00667615
View directory record Official record
Conditions
Hodgkin's Disease, Lymphoma
Interventions
rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 10, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional Results available

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

NCT01930890
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BIIB023, mycophenolate mofetil, oral corticosteroids
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 76 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Lake Success, New York • Columbus, Ohio • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 10, 2026, 6:26 AM EDT
Terminated Phase 1 Interventional Results available

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

NCT02574910
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Abiraterone acetate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 9 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 10, 2026, 6:26 AM EDT
Terminated Phase 1 Interventional

The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children

NCT03040596
View directory record Official record
Conditions
Vocal Fold Nodules
Interventions
Fluticasone propionate, Standard voice therapy
Drug · Behavioral
Lead sponsor
Joseph Dohar, MD
Other
Eligibility
4 Years to 11 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 10, 2026, 6:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 10, 2026, 6:26 AM EDT
Completed No phase listed Observational

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

NCT01988285
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Specimen Collection, Questionnaires
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 10, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional Results available

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

NCT02337517
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Laboratory Biomarker Analysis, Vismodegib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 10, 2026, 6:26 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT04851613
View directory record Official record
Conditions
Breast Cancer
Interventions
Afuresertib, Afuresertib/placebo
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 10, 2026, 6:26 AM EDT
Withdrawn Not applicable Interventional

Vitamin D Treatment in Ulcerative Colitis

NCT01640496
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Vitamin D3, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

NCT00499408
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vitamin D, soy
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

NCT01159574
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, clarithromycin, Pomalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 10, 2026, 6:26 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Progesterone in Gender Affirming Hormone Therapy Study

NCT06807580
View directory record Official record
Conditions
Transgender Women
Interventions
Placebo, Progesterone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Not applicable Interventional Results available

Acupuncture Therapy for COVID-Related Olfactory Loss

NCT04952389
View directory record Official record
Conditions
Olfactory Dysfunction, COVID-19
Interventions
Acupuncture Therapy, Budesonide, Olfactory Training
Device · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 10, 2026, 6:26 AM EDT
Active, not recruiting Early Phase 1 Interventional

Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation

NCT03929718
View directory record Official record
Conditions
AFib
Interventions
Spironolactone, No Spironolactone
Drug
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

NCT01436110
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 10, 2026, 6:26 AM EDT
Terminated Phase 1 Interventional

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

NCT01868360
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Subconjunctival aflibercept, Placebo: Standard of care only
Drug · Other
Lead sponsor
Balamurali Ambati
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

NCT05512962
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Triamcinolone Acetonide, Semi-automated Suprachoroidal Microcatheter
Drug · Device
Lead sponsor
Oxular Limited
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Bakersfield, California • Minneapolis, Minnesota • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PREGNANT Short Cervix Trial

NCT00615550
View directory record Official record
Conditions
Preterm Delivery, Short Cervix, Short Uterine Cervical Length
Interventions
progesterone, placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 10, 2026, 6:26 AM EDT
Recruiting Phase 1 Interventional

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

NCT06233110
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 10, 2026, 6:26 AM EDT
Active, not recruiting Phase 3 Interventional

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Fulvestrant, Alpelisib
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
71
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 10, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Everolimus Beyond Progression

NCT02269670
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 10, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Results available

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

NCT00304746
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Testosterone gel, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 10, 2026, 6:26 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

NCT04653246
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Interventions
Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
Drug
Lead sponsor
Jacob Laubach, MD
Other
Eligibility
75 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 10, 2026, 6:26 AM EDT